BridgeBio to Present 42-Month Outcomes from ATTRibute-CM Phase 3 Study at 2024 AHA Sessions

BridgeBio Pharma, Inc., a biopharmaceutical company based in PALO ALTO, Calif., has announced significant outcomes data from its long-term open-label extension of the ATTRibute-CM Phase 3 study of acoramidis in treating ATTR-CM. This data, collected over 42 months, will be presented during the American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, from November 16 to 18, 2024.

Acoramidis is being investigated for its potential to reduce all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Daniel Judge, M.D., from the Medical University of South Carolina, will present the initial outcomes from this study in a featured science oral presentation. This session, titled "Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations," is scheduled for Monday, November 18 at 9:45 am CT/10:45 am ET.

In addition to the oral presentation, BridgeBio will also present three posters in moderated poster sessions focused on ATTR-CM. These posters will highlight various aspects of the disease and treatment approaches:

1. **Costs and Healthcare Resource Utilization in Transthyretin Amyloid Cardiomyopathy Exceeds That of Generalized Heart Failure**: Presented by Justin Grodin, M.D., from UT Southwestern Medical Center, this poster will be showcased on Sunday, November 17 at 10:00 am CT/11:00 am ET under the session title "Socioeconomic Insights and Innovations in Heart Failure."

2. **Evolving Baseline Risk in Patients with Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials**: Ahmad Masri, M.D., from Oregon Health & Science University, will present this review on Sunday, November 17 at 11:10 am CT/12:10 pm ET during the session "Cardiac Amyloidosis 2024: Advances in Prognostication and Management."

3. **Acoramidis Improved Survival in Patients with Transthyretin Cardiac Amyloidosis Regardless of Prior Cardiovascular Hospitalization**: This poster, presented by Kevin Alexander, M.D., from Stanford University School of Medicine, will be part of the same session as the previous poster and is scheduled for Sunday, November 17 at 11:20 am CT/12:20 pm ET.

Following these sessions, the presentation and posters will be made available on the Presentations page within the Investors section of the BridgeBio website.

BridgeBio Pharma is a commercial-stage biopharmaceutical company that was founded with the mission to discover, develop, and deliver transformative medicines for patients with genetic diseases. Since its establishment in 2015, the company has built a robust pipeline of development programs that span from early scientific research to advanced clinical trials. The team at BridgeBio includes experienced professionals in the field of drug discovery and development, all dedicated to leveraging advances in genetic medicine to expedite the delivery of new treatments to patients in need.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!